Physician profile
Ravi Dukkipati
NPI 1710958434
$935,772.69
in general payments reported to CMS, 2019-2025
26 companies · $187K in 2025
The $187K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $105K · 2021: $157K · 2022: $166K · 2023: $205K · 2024: $100K · 2025: $187K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $357K · Consulting Fee: $79K · Travel and Lodging: $45K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $356,905.00 |
| Consulting Fee | $78,503.75 |
| Travel and Lodging | $44,848.52 |
| Food and Beverage | $11,970.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $747,356.73 | 2019-2025 | Mavenclad, Mavenclad |
| Merck Kgaa | $46,285.43 | 2020-2022 | |
| Tg Therapeutics, INC. | $44,860.92 | 2021-2025 | Briumvi |
| E.R. Squibb & Sons, L.L.C. | $24,412.82 | 2021-2025 | Zeposia |
| Celgene Corporation | $24,114.56 | 2019-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $17,620.86 | 2019-2025 | Kesimpta |
| Genentech USA, INC. | $11,075.22 | 2019-2025 | Ocrevus, Enspryng |
| Abbvie INC. | $7,232.10 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Genzyme Corporation | $4,168.95 | 2021-2025 | |
| Genentech, INC. | $2,885.28 | 2021-2024 | Ocrevus |
| Horizon Therapeutics Plc | $1,916.81 | 2021-2023 | Uplizna |
| Janssen Pharmaceuticals, INC | $1,080.00 | 2021 | |
| Cycle Pharmaceuticals INC | $1,060.00 | 2023 | |
| Biogen, INC. | $593.44 | 2019-2025 | Tysabri |
| Allergan, INC. | $488.01 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $200.00 | 2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $115.98 | 2019-2023 | Ajovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $93.02 | 2022 | |
| Pfizer INC. | $84.02 | 2023-2025 | |
| Lundbeck LLC | $28.30 | 2025 | Vyepti |
| Sanofi-Aventis U.S. LLC | $23.68 | 2021 | |
| Lilly USA, LLC | $19.76 | 2024 | Kisunla, Amyvid |
| Ani Pharmaceuticals, INC. | $17.45 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.46 | 2023 | Acthar |
| Mallinckrodt Enterprises LLC | $13.73 | 2019 | |
| Akcea Therapeutics, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Dukkipati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.